Benitec engages Ernst & Young as auditor for fiscal year ending June 30, 2027

Benitec Biopharma Inc.

EY completed its client acceptance process on September 28, 2026, and executed the engagement letter with Benitec on September 29, 2026.
The EY engagement covers the fiscal year ending June 30, 2027; the approval was previously disclosed in a Form 8-K filed September 24, 2026.
Filing is an Item 4.01 change-in-certifying-accountant notice; no resignation, disagreement, or restatement disclosure is provided.
Signed by Chief Executive Officer Dr. Jerel A. Banks, dated September 30, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.